Fabrazyme Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Fabrazyme is a prescription medication primarily used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency results in the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues, leading to serious health complications such as kidney damage, heart issues, and neurological problems.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of fabrazyme include the 5 mg/vial and 35 mg/vial formulations. The 5 mg/vial refers to Fabrazyme supplied in single-dose vials containing 5 milligrams of the active ingredient, agalsidase beta. These formulations are used in hospitals and drug stores, with end users including both pediatric and adult patients.

The fabrazyme market research report is one of a series of new reports from The Business Research Company that provides fabrazyme market statistics, including fabrazyme industry global market size, regional shares, competitors with a fabrazyme market share, detailed fabrazyme market segments, market trends and opportunities, and any further data you may need to thrive in the fabrazyme industry. This fabrazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fabrazyme market size is expected to see rapid growth in the next few years. It will grow to $2,079.6 million in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing recognition of Fabry disease, advancements in genetic testing, rising patient population, regulatory Support and reimbursement policies, and focus on rare diseases. Major trends in the forecast period include increasing diagnosis rates, technological advancements, emerging market expansion, sustainability initiatives, and digital transformation.

The increasing prevalence of genetic disorders is expected to drive the growth of the fabrazyme market. Genetic disorders are health conditions caused by abnormalities in an individual's genetic material. The rise in genetic disorders is largely due to advanced diagnostic technologies detecting more cases, along with factors like delayed parenthood, environmental influences, and lifestyle changes contributing to genetic mutations. Fabrazyme, an enzyme replacement therapy, is used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. It helps break down certain lipids that accumulate in the body, reducing organ damage risk, alleviating symptoms, and improving overall quality of life. For instance, in March 2024, Gene People, a UK-based charity, reported that over 6,000 genetic conditions are diagnosed in the UK, affecting approximately 1 in 25 children. This results in about 30,000 new diagnoses annually, with more than 2.4 million people currently living with a genetic condition. Therefore, the rising number of genetic disorders is propelling the fabrazyme market.

Increasing healthcare expenditure is expected to further drive the growth of the fabrazyme market. Healthcare expenditure refers to the total amount spent on health services and related activities, typically measured annually. The rise in healthcare expenditure is attributed to factors such as an aging population, chronic diseases, higher service prices, increased demand, technological advancements, and rising drug costs. Fabrazyme addresses the underlying causes of Fabry disease through enzyme replacement therapy, which benefits from increased healthcare spending as it allows for better disease management, reduces the need for costly emergency interventions, and ultimately improves patient outcomes. For example, the National Library of Medicine reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, faster than the 3.2% growth seen in 2021. Therefore, rising healthcare expenditure is fueling the growth of the fabrazyme market.

The rise of personalized medicine is expected to contribute to the growth of the fabrazyme market. Personalized medicine is a treatment approach that tailors healthcare strategies to an individual's genetic makeup, environment, and lifestyle, aiming for more effective and precise outcomes. The rise in personalized medicine is driven by advancements in genomic technologies, a greater understanding of molecular biology, increased availability of precision diagnostic tools, and a demand for targeted therapies that enhance patient outcomes while minimizing side effects. Fabrazyme supports personalized medicine by providing enzyme replacement therapy tailored to the specific genetic and metabolic needs of patients with Fabry disease, improving therapeutic efficacy and clinical outcomes. For example, in 2022, the FDA approved personalized medicines for 34% of new drugs, according to the Personalized Medicine Coalition. This demonstrates the growing trend in personalized medicine, which is driving the fabrazyme market forward.

Major players operating in the fabrazyme market are Sanofi S.A., JCR Pharmaceuticals, mAbxience

North America was the largest region in the Fabrazyme market in 2024. The regions covered in fabrazyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabrazyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabrazyme market consists of sales of the enzyme replacement therapy (ERT) known as Fabrazyme (agalsidase beta), Replagal (agalsidase alpha), Oral Chaperone Therapies, Substrate Reduction Therapies (SRT). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabrazyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabrazyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabrazyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabrazyme market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 5mg/vial; 35mg/vial
• 2) By Indication: Fabry Disease; Renal Impairment; Cardiac Involvement; Neuropathic Pain; Stroke Prevention
• 2) By Application: Hospital; Drug store
• 3) By End-User: Pediatric; Adult
• Companies Mentioned: Sanofi S.A.; JCR Pharmaceuticals; mAbxience
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.